ES2914685T3 - Broncodilatador para su uso en un método de tratamiento de la broncoconstricción junto con la estimulación del nervio vago - Google Patents
Broncodilatador para su uso en un método de tratamiento de la broncoconstricción junto con la estimulación del nervio vago Download PDFInfo
- Publication number
- ES2914685T3 ES2914685T3 ES16760189T ES16760189T ES2914685T3 ES 2914685 T3 ES2914685 T3 ES 2914685T3 ES 16760189 T ES16760189 T ES 16760189T ES 16760189 T ES16760189 T ES 16760189T ES 2914685 T3 ES2914685 T3 ES 2914685T3
- Authority
- ES
- Spain
- Prior art keywords
- signal
- nerve
- bronchodilator
- patient
- fibers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001186 vagus nerve Anatomy 0.000 title claims abstract description 153
- 206010006482 Bronchospasm Diseases 0.000 title claims abstract description 114
- 229940124630 bronchodilator Drugs 0.000 title claims abstract description 108
- 230000007885 bronchoconstriction Effects 0.000 title claims abstract description 101
- 238000000034 method Methods 0.000 title claims abstract description 67
- 230000007383 nerve stimulation Effects 0.000 title description 9
- 230000001537 neural effect Effects 0.000 claims abstract description 192
- 210000005036 nerve Anatomy 0.000 claims description 169
- 230000000638 stimulation Effects 0.000 claims description 109
- 230000036982 action potential Effects 0.000 claims description 81
- 238000011282 treatment Methods 0.000 claims description 54
- 210000005091 airway smooth muscle Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 29
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 26
- 210000004072 lung Anatomy 0.000 claims description 26
- 230000007423 decrease Effects 0.000 claims description 25
- 230000002685 pulmonary effect Effects 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- 230000001734 parasympathetic effect Effects 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 13
- 239000001569 carbon dioxide Substances 0.000 claims description 12
- 230000036387 respiratory rate Effects 0.000 claims description 11
- 230000002889 sympathetic effect Effects 0.000 claims description 11
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 10
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 10
- 230000002085 persistent effect Effects 0.000 claims description 6
- 230000006461 physiological response Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000000835 fiber Substances 0.000 description 125
- 230000004007 neuromodulation Effects 0.000 description 50
- 230000000694 effects Effects 0.000 description 47
- 208000006673 asthma Diseases 0.000 description 38
- 210000004126 nerve fiber Anatomy 0.000 description 29
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 26
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 22
- 230000004936 stimulating effect Effects 0.000 description 21
- 239000000168 bronchodilator agent Substances 0.000 description 18
- 230000004044 response Effects 0.000 description 16
- 210000003437 trachea Anatomy 0.000 description 16
- 230000003287 optical effect Effects 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 208000009079 Bronchial Spasm Diseases 0.000 description 13
- 208000014181 Bronchial disease Diseases 0.000 description 13
- 230000007883 bronchodilation Effects 0.000 description 13
- 230000007781 signaling event Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 230000029058 respiratory gaseous exchange Effects 0.000 description 12
- 229930003347 Atropine Natural products 0.000 description 11
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 11
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 11
- 229960000396 atropine Drugs 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000001515 vagal effect Effects 0.000 description 11
- 230000008602 contraction Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000002604 ultrasonography Methods 0.000 description 9
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 8
- 230000001066 destructive effect Effects 0.000 description 8
- 229960002052 salbutamol Drugs 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 244000025254 Cannabis sativa Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000011514 reflex Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000005279 Status Asthmaticus Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 230000007748 combinatorial effect Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 206010021118 Hypotonia Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000036640 muscle relaxation Effects 0.000 description 3
- 230000007372 neural signaling Effects 0.000 description 3
- 230000003227 neuromodulating effect Effects 0.000 description 3
- 210000005037 parasympathetic nerve Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000013479 data entry Methods 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000003270 subclavian artery Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000009284 tracheal contraction Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003801 laryngeal nerve Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 210000000584 nodose ganglion Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000002416 recurrent laryngeal nerve Anatomy 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035909 sensory irritation Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008625 synaptic signaling Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/0816—Measuring devices for examining respiratory frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/087—Measuring breath flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/091—Measuring volume of inspired or expired gases, e.g. to determine lung capacity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/388—Nerve conduction study, e.g. detecting action potential of peripheral nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4035—Evaluating the autonomic nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36057—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for stimulating afferent nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/3611—Respiration control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Optics & Photonics (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208057P | 2015-08-21 | 2015-08-21 | |
| PCT/IB2016/054957 WO2017033101A1 (en) | 2015-08-21 | 2016-08-18 | Neuromodulation device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2914685T3 true ES2914685T3 (es) | 2022-06-15 |
Family
ID=56853696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16760189T Active ES2914685T3 (es) | 2015-08-21 | 2016-08-18 | Broncodilatador para su uso en un método de tratamiento de la broncoconstricción junto con la estimulación del nervio vago |
| ES22169569T Active ES2982192T3 (es) | 2015-08-21 | 2016-08-18 | Dispositivo de neuromodulación |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22169569T Active ES2982192T3 (es) | 2015-08-21 | 2016-08-18 | Dispositivo de neuromodulación |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11878160B2 (enExample) |
| EP (2) | EP4052756B1 (enExample) |
| JP (1) | JP2018523542A (enExample) |
| KR (1) | KR20180044941A (enExample) |
| CN (1) | CN108367151A (enExample) |
| AU (1) | AU2016310626A1 (enExample) |
| BR (1) | BR112018003107A2 (enExample) |
| CA (1) | CA2996252A1 (enExample) |
| ES (2) | ES2914685T3 (enExample) |
| RU (1) | RU2018105336A (enExample) |
| WO (1) | WO2017033101A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3538211A1 (en) * | 2016-11-11 | 2019-09-18 | Galvani Bioelectronics Limited | Treatment of diseases mediated by thyroid and parathyroid hormones |
| CN109045468B (zh) * | 2018-08-09 | 2022-05-24 | 西安科悦医疗技术有限公司 | 一种耳部迷走神经刺激系统及其装置 |
| US20230139790A1 (en) * | 2020-01-23 | 2023-05-04 | Saluda Medical Pty Ltd | Neuromodulation of Primary and/or Postsynaptic Neurons |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993002744A1 (en) | 1991-08-09 | 1993-02-18 | Cyberonics, Inc. | Treatment of anxiety disorders by nerve stimulation |
| AU2005323463B2 (en) * | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
| US8660647B2 (en) | 2005-07-28 | 2014-02-25 | Cyberonics, Inc. | Stimulating cranial nerve to treat pulmonary disorder |
| EP1948301B8 (en) * | 2005-11-10 | 2014-03-12 | ElectroCore LLC | Electrical stimulation treatment of bronchial constriction |
| US8874227B2 (en) * | 2009-03-20 | 2014-10-28 | ElectroCore, LLC | Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient |
| US8812112B2 (en) * | 2005-11-10 | 2014-08-19 | ElectroCore, LLC | Electrical treatment of bronchial constriction |
| US20100217347A1 (en) * | 2006-12-16 | 2010-08-26 | Greatbatch, Inc. | Neurostimulation for the treatment of pulmonary disorders |
| US8483831B1 (en) * | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| WO2009137819A1 (en) * | 2008-05-09 | 2009-11-12 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
| US8843210B2 (en) * | 2009-03-20 | 2014-09-23 | ElectroCore, LLC | Non-invasive vagal nerve stimulation to treat disorders |
| US20120302909A1 (en) * | 2009-11-11 | 2012-11-29 | Mayse Martin L | Methods and systems for screening subjects |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| JP2015008746A (ja) * | 2013-06-26 | 2015-01-19 | オリンパス株式会社 | 神経刺激装置、副作用予測装置および神経刺激装置の作動方法 |
| US10639477B2 (en) | 2014-01-17 | 2020-05-05 | Cardiac Pacemakers, Inc. | Systems and methods for delivering pulmonary therapy |
| US9737716B2 (en) * | 2014-08-12 | 2017-08-22 | Cyberonics, Inc. | Vagus nerve and carotid baroreceptor stimulation system |
-
2016
- 2016-08-18 KR KR1020187007903A patent/KR20180044941A/ko not_active Withdrawn
- 2016-08-18 US US15/752,502 patent/US11878160B2/en active Active
- 2016-08-18 AU AU2016310626A patent/AU2016310626A1/en not_active Abandoned
- 2016-08-18 EP EP22169569.5A patent/EP4052756B1/en active Active
- 2016-08-18 ES ES16760189T patent/ES2914685T3/es active Active
- 2016-08-18 WO PCT/IB2016/054957 patent/WO2017033101A1/en not_active Ceased
- 2016-08-18 CN CN201680061734.8A patent/CN108367151A/zh active Pending
- 2016-08-18 CA CA2996252A patent/CA2996252A1/en not_active Abandoned
- 2016-08-18 RU RU2018105336A patent/RU2018105336A/ru not_active Application Discontinuation
- 2016-08-18 JP JP2018509502A patent/JP2018523542A/ja active Pending
- 2016-08-18 BR BR112018003107A patent/BR112018003107A2/pt not_active Application Discontinuation
- 2016-08-18 EP EP16760189.7A patent/EP3337556B1/en active Active
- 2016-08-18 ES ES22169569T patent/ES2982192T3/es active Active
-
2023
- 2023-12-12 US US18/537,151 patent/US20240131327A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2996252A1 (en) | 2017-03-02 |
| CN108367151A (zh) | 2018-08-03 |
| WO2017033101A1 (en) | 2017-03-02 |
| EP3337556B1 (en) | 2022-05-25 |
| EP4052756B1 (en) | 2024-05-15 |
| EP4052756A1 (en) | 2022-09-07 |
| EP3337556A1 (en) | 2018-06-27 |
| BR112018003107A2 (pt) | 2018-09-25 |
| KR20180044941A (ko) | 2018-05-03 |
| US11878160B2 (en) | 2024-01-23 |
| US20180236224A1 (en) | 2018-08-23 |
| ES2982192T3 (es) | 2024-10-15 |
| AU2016310626A1 (en) | 2018-03-08 |
| JP2018523542A (ja) | 2018-08-23 |
| RU2018105336A (ru) | 2019-09-23 |
| US20240131327A1 (en) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12377270B2 (en) | Systems and methods for the treatment of pain through neural fiber stimulation | |
| CN111565791B (zh) | 外周神经电极阵列 | |
| JP2023055798A (ja) | 呼吸機能を可能にするための、脊髄ネットワークへのアクセス | |
| US10639477B2 (en) | Systems and methods for delivering pulmonary therapy | |
| CA2808606C (en) | Non-invasive treatment of bronchial constriction | |
| Onders et al. | Final analysis of the pilot trial of diaphragm pacing in amyotrophic lateral sclerosis with long-term follow-up: diaphragm pacing positively affects diaphragm respiration | |
| US20240131327A1 (en) | Neuromodulation Device | |
| ES2855799T3 (es) | Dispositivo de neuromodulación | |
| US10076666B2 (en) | Systems and methods for treating post-traumatic stress disorder | |
| JP2018524113A (ja) | 呼吸機能を可能にするために脊髄ネットワークにアクセスすること | |
| JP2009515670A (ja) | 睡眠時無呼吸症防止のために横隔神経を刺激する装置および方法 | |
| US20250082937A1 (en) | Neuromodulation device | |
| KR20200103037A (ko) | 단방향 자극 및 전류 스티어링을 위한 신경 자극 디바이스 | |
| Su et al. | Restoring the autonomic balance in an atrial fibrillation rat model by electroacupuncture at the neiguan point | |
| Abdunnur et al. | Phrenic nerve stimulation: technology and clinical applications | |
| ES2922929T3 (es) | Dispositivo de neuromodulación | |
| JP2018523542A5 (enExample) | ||
| Guo et al. | Epidural combined optical and electrical stimulation induces high-specificity activation of target muscles in spinal cord injured rats | |
| KR20250019024A (ko) | 신경 자극용 치료제를 전달하기 위한 시스템, 디바이스, 및 방법 | |
| Sabetian et al. | Optimizing a novel nerve cuff electrode to record bidirectional neural activity | |
| Velazco et al. | Phrenic nerve pacing: current concepts | |
| Pralong et al. | P27. 11 Excitatory and inhibitory effects of internal globus pallidus stimulation on pallidal neurons | |
| Malaguti et al. | P27. 9 Intraoperative neurophysiological monitoring of pudendal nerve activity during pudendal nerve implant for neurogenic overactive bladder |